Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), scheduled for May 12-16, 2026 in Padua, Italy. The event, hosted by the University of Padova, will focus on advanced cardiovascular imaging and artificial intelligence—areas where Ventripoint is making clinical progress.
AEPC, founded in 1963, is the world’s largest association in congenital cardiology, with over 1,000 specialists from 32 European countries. The meeting provides a platform for Ventripoint to engage with clinicians and showcase its VMS+™ product family, which is powered by proprietary KBR technology developed over more than a decade. The company will exhibit alongside its European distributor, AngioPro.
A key focus at Ventripoint's booth will be the ability of VMS+™ to support longitudinal assessment of cardiac function in congenital heart disease (CHD) patients. This approach aligns with the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up. The guidelines affirm echocardiography as the key modality for ventricular function assessment (Baumgartner et al., European Heart Journal, 2021; doi:10.1093/eurheartj/ehaa554).
Ventripoint’s priority for 2026 is accelerating integration of VMS+™ into routine clinical practice. The latest release, VMS+™ 4.0, was built around clinician needs to streamline workflows and reduce assessment time, making advanced cardiac analysis accessible at the point of care. From a patient’s first echocardiogram, VMS+™ provides volumetric cardiac measurements equivalent to MRI, supporting clinical decision-making across a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI—giving clinicians the confidence they need to manage their patients at every stage of life.”
The company’s technology is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada. For further information, refer to Ventripoint’s profile on SEDAR at www.sedar.com. The original release is available at www.newmediawire.com.
